2020 -- H 7510

========

LC004388

========

     STATE OF RHODE ISLAND

IN GENERAL ASSEMBLY

JANUARY SESSION, A.D. 2020

____________

A N   A C T

RELATING TO BUSINESSES AND PROFESSIONS -- PHARMACIES

     

     Introduced By: Representatives McEntee, Craven, Caldwell, McKiernan, and
Speakman

     Date Introduced: February 07, 2020

     Referred To: House Health, Education & Welfare

     It is enacted by the General Assembly as follows:

1

     SECTION 1. Section 5-19.1-2 of the General Laws in Chapter 5-19.1 entitled

2

"Pharmacies" is hereby amended to read as follows:

3

     5-19.1-2. Definitions.

4

     (a) "Biological product" means a "biological product" as defined in the "Public Health

5

Service Act," 42 U.S.C. § 262.

6

     (b) "Board" means the Rhode Island board of pharmacy.

7

     (c) "Change of ownership" means:

8

     (1) In the case of a pharmacy, manufacturer, or wholesaler that is a partnership, any

9

change that results in a new partner acquiring a controlling interest in the partnership;

10

     (2) In the case of a pharmacy, manufacturer, or wholesaler that is a sole proprietorship,

11

the transfer of the title and property to another person;

12

     (3) In the case of a pharmacy, manufacturer, or wholesaler that is a corporation:

13

     (i) A sale, lease exchange, or other disposition of all, or substantially all, of the property

14

and assets of the corporation; or

15

     (ii) A merger of the corporation into another corporation; or

16

     (iii) The consolidation of two (2) or more corporations resulting in the creation of a new

17

corporation; or

18

     (iv) In the case of a pharmacy, manufacturer, or wholesaler that is a business corporation,

19

any transfer of corporate stock that results in a new person acquiring a controlling interest in the

 

1

corporation; or

2

     (v) In the case of a pharmacy, manufacturer, or wholesaler that is a non-business

3

corporation, any change in membership that results in a new person acquiring a controlling vote

4

in the corporation.

5

     (d) "Compounding" means the act of combining two (2) or more ingredients as a result of

6

a practitioner's prescription or medication order occurring in the course of professional practice

7

based upon the individual needs of a patient and a relationship between the practitioner, patient,

8

and pharmacist. Compounding does not mean the routine preparation, mixing, or assembling of

9

drug products that are essentially copies of a commercially available product. Compounding shall

10

only occur in the pharmacy where the drug or device is dispensed to the patient or caregiver and

11

includes the preparation of drugs or devices in anticipation of prescription orders based upon

12

routine, regularly observed prescribing patterns.

13

     (e) "Controlled substance" means a drug or substance, or an immediate precursor of such

14

drug or substance, so designated under, or pursuant to, the provisions of chapter 28 of title 21.

15

     (f) "Deliver" or "delivery" means the actual, constructive, or attempted transfer from one

16

person to another of a drug or device, whether or not there is an agency relationship.

17

     (g) "Device" means instruments, apparatus, and contrivances, including their

18

components, parts, and accessories, intended:

19

     (1) For use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man

20

or other animals; or

21

     (2) To affect the structure or any function of the body of humans or other animals.

22

     (h) "Director" means the director of the Rhode Island state department of health.

23

     (i) "Dispense" means the interpretation of a prescription or order for a drug, biological, or

24

device and, pursuant to that prescription or order, the proper selection, measuring, compounding,

25

labeling, or packaging necessary to prepare that prescription or order for delivery or

26

administration.

27

     (j) "Distribute" means the delivery of a drug or device other than by administering or

28

dispensing.

29

     (k) "Drug" means:

30

     (1) Articles recognized in the official United States Pharmacopoeia or the Official

31

Homeopathic Pharmacopoeia of the U.S.;

32

     (2) Substances intended for use in the diagnosis, cure, mitigation, treatment, or

33

prevention of disease in humans or other animals;

34

     (3) Substances (other than food) intended to affect the structure, or any function, of the

 

LC004388 - Page 2 of 6

1

body of humans or other animals; or

2

     (4) Substances intended for use as a component of any substances specified in subsection

3

(k)(1), (k)(2), or (k)(3), but not including devices or their component parts or accessories.

4

     (l) "Equivalent and interchangeable" means a drug, excluding a biological product,

5

having the same generic name, dosage form, and labeled potency, meeting standards of the

6

United States Pharmacopoeia or National Formulary, or their successors, if applicable, and not

7

found in violation of the requirements of the United States Food and Drug Administration, or its

8

successor agency, or the Rhode Island department of health.

9

     (m) "Interchangeable biological product" means a biological product that the United

10

States Food and Drug Administration has:

11

     (1) Licensed and determined meets the standards for interchangeability pursuant to 42

12

U.S.C. § 262(k)(4) or lists of licensed, biological products with reference product exclusivity and

13

biosimilarity or interchangeability evaluations; or

14

     (2) Determined is therapeutically equivalent as set forth in the latest edition of, or

15

supplement to, the United States Food and Drug Administration's Approved Drug Products with

16

Therapeutic Equivalence Evaluations.

17

     (n) "Intern" means:

18

     (1) A graduate of an American Council on Pharmaceutical Education (ACPE)-accredited

19

program of pharmacy;

20

     (2) A student who is enrolled in at least the first year of a professional ACPE-accredited

21

program of pharmacy; or

22

     (3) A graduate of a foreign college of pharmacy who has obtained full certification from

23

the FPGEC (Foreign Pharmacy Graduate Equivalency Commission) administered by the National

24

Association of Boards of Pharmacy.

25

     (o) "Legend drugs" means any drugs that are required by any applicable federal or state

26

law or regulation to be dispensed on prescription only or are restricted to use by practitioners

27

only.

28

     (p) "Limited-function test" means those tests listed in the federal register under the

29

Clinical Laboratory Improvement Amendments of 1988 (CLIA) as waived tests. For the purposes

30

of this chapter, limited-function test shall include only the following: blood glucose, hemoglobin

31

A1c, cholesterol tests, and/or other tests that are classified as waived under CLIA and are

32

approved by the United States Food and Drug Administration for sale to the public without a

33

prescription in the form of an over-the-counter test kit.

34

     (q) "Manufacture" means the production, preparation, propagation, compounding, or

 

LC004388 - Page 3 of 6

1

processing of a drug or other substance or device or the packaging or repackaging.

2

     (r) "Non-legend" or "nonprescription drugs" means any drugs that may be lawfully sold

3

without a prescription.

4

     (s) "Person" means an individual, corporation, government, subdivision, or agency,

5

business trust, estate, trust, partnership, or association, or any other legal entity.

6

     (t) "Pharmaceutical care" is the provision of drugs and other pharmaceutical services

7

intended to achieve outcomes related to cure or prevention of a disease, elimination or reduction

8

of a patient's symptoms, or arresting or slowing of a disease process. "Pharmaceutical care"

9

includes the judgment of a pharmacist in dispensing an equivalent and interchangeable drug or

10

device in response to a prescription after appropriate communication with the prescriber and the

11

patient.

12

     (u) "Pharmacist in charge" means a pharmacist licensed in this state as designated by the

13

owner as the person responsible for the operation of a pharmacy in conformance with all laws and

14

regulations pertinent to the practice of pharmacy and who is personally in full and actual charge

15

of such pharmacy and personnel.

16

     (v) "Pharmacy" means that portion or part of a premise where prescriptions are

17

compounded and dispensed, including that portion utilized for the storage of prescription or

18

legend drugs.

19

     (w) "Pharmacy technician" means an individual who meets minimum qualifications

20

established by the board, that are less than those established by this chapter as necessary for

21

licensing as a pharmacist, and who works under the direction and supervision of a licensed

22

pharmacist.

23

     (x) "Practice of pharmacy" means the interpretation, evaluation, and implementation of

24

medical orders; the dispensing of prescription drug orders; participation in drug and device

25

selection; the compounding of prescription drugs; drug regimen reviews and drug or drug-related

26

research; the administration of adult immunizations and medications pursuant to a valid

27

prescription or physician-approved protocol and in accordance with regulations, to include

28

training requirements as promulgated by the department of health; the administration of all forms

29

of influenza immunizations to individuals between the ages of nine (9) years and eighteen (18)

30

years, inclusive, pursuant to a valid prescription or prescriber-approved protocol, in accordance

31

with the provisions of § 5-19.1-31 and in accordance with regulations, to include necessary

32

training requirements specific to the administration of influenza immunizations to individuals

33

between the ages of nine (9) years and eighteen (18) years, inclusive, as promulgated by the

34

department of health; provision of patient counseling and the provision of those acts or services

 

LC004388 - Page 4 of 6

1

necessary to provide pharmaceutical care; the responsibility for the supervision for compounding

2

and labeling of drugs and devices (except labeling by a manufacturer, repackager, or distributor

3

of nonprescription drugs and commercially packaged legend drugs and devices), proper and safe

4

storage of drugs and devices, and maintenance of proper records for them; and the performance of

5

clinical laboratory tests, provided such testing is limited to limited-function tests as defined

6

herein. Nothing in this definition shall be construed to limit or otherwise affect the scope of

7

practice of any other profession.

8

     (y) "Practitioner" means a physician, dentist, veterinarian, nurse, or other person duly

9

authorized by law in the state in which they practice to prescribe drugs.

10

     (z) "Preceptor" means a pharmacist registered to engage in the practice of pharmacy in

11

this state who has the responsibility for training interns.

12

     (aa) "Prescription" means an order for drugs or devices issued by the practitioner duly

13

authorized by law in the state in which he or she practices to prescribe drugs or devices in the

14

course of his or her professional practice for a legitimate medical purpose.

15

     (bb) "Wholesaler" means a person who buys drugs or devices for resale and distribution

16

to corporations, individuals, or entities other than consumers.

17

     SECTION 2. This act shall take effect on January 1, 2021.

========

LC004388

========

 

LC004388 - Page 5 of 6

EXPLANATION

BY THE LEGISLATIVE COUNCIL

OF

A N   A C T

RELATING TO BUSINESSES AND PROFESSIONS -- PHARMACIES

***

1

     This act would amend the definition of the "practice of pharmacy" to include the

2

administration of adult medications pursuant to a valid prescription of physician-approved

3

protocol and in accordance with regulations.

4

     This act would take effect on January 1, 2021.

========

LC004388

========

 

LC004388 - Page 6 of 6